Boston Scientific Announces New Data on Precision Spectra SCS’ Efficacy in Pain Relief

Boston Scientific announced new retrospective data related to its Precision Spectra Spinal Cord Stimulator, which shows that it provides sustained and significant low-back pain relief six months after implementation.

Advertisement

The retrospective study focuses on 213 patients at 13 centers with chronic pain who were treated with the system. To date, 140 patients have reached the six months post-implant point.

 

The study found that there was a reduction in pain from an average baseline score of 7.15, on a 10-point scale, to an average score of 2.93 at the six month mark. In patients with severe back pain, there was a reduction from an average score of 8.78 at baseline to 3.68 at six months post-implant.

More Articles on Devices:

5 Key Results: LDR’s Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.